Targeted Oncology Staff

During a live virtual event, Adam M. Schoenfeld, MD, discussed results of the KEYNOTE-407 trial of patients with advanced squamous non–small cell lung cancer in terms of PD-L1 expression. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Rana R. McKay, MD, discussed the case of a patient who progressed following treatment with axitinib and pembrolizumab for clear cell renal cell carcinoma.

During a live virtual event, Roby A. Thomas, MD, discussed the choice of therapy for a patient with metastatic castration-sensitive prostate cancer.

During a Targeted Oncology case-based roundtable event, Mohamed K. Mohamed, MD, PhD, discussed with participants the challenges of treating extensive-stage small cell lung cancer and their views of the CASPIAN and IMpower 133 trial results.

During a Targeted Oncology case-based roundtable discussion, Mehdi H. Hamadani, MD, discussed systemic therapy options for relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Larry D. Anderson, MD, PhD, discussed the results of the DREAMM-2 trial and management of belantamab mafodotin for patients with multiple myeloma.

During a live virtual event, Ulka N. Vaishampayan, MBBS, discussed the choice of first-line therapy for clear cell renal cell carcinoma and whether the approach to treatment would change with other disease histologies.

During a live virtual event, Caitlin Costello, MD, discussed the rationale for choosing a triplet or quadruplet regimen for patients with transplant-eligible newly diagnosed multiple myeloma.

During a Targeted Oncology case-based roundtable event, Cyrus M. Khan, MD, discussed the data supporting the use of polatuzumab, bendamustine, and rituximab, tasfasitamab plus lenalidomide, and loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, discussed therapeutic sequencing for patients with unresectable hepatocellular carcinoma and the use of lenvatinib versus sorafenib.

During a live virtual event, Christine Bestvina, MD, discussed the use of amivantamab and mobocertinib, 2 new targeted therapies for patients with non–small cell lung cancer and an EGFR exon 20 insertion.

During a Targeted Oncology case-based roundtable event, Pedro Barata, MD, MSc, discussed the case of a patient with clear cell renal cell carcinoma who progressed following frontline treatment with axitinib/pembrolizumab.

During a case-based roundtable event, David A. Rizzieri, MD, discussed the case of a 68-year-old patient with myelofibrosis.

Michael R. Bishop, MD, discussed a patient with graft-versus-host disease who first underwent a myeloablative conditioning regimen and peripheral blood stem-cell matched hematopoietic cell transplant as treatment.

Experts discuss the newest approaches for treating patients with diffuse large B-cell lymphoma.

During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the VISION trial supporting the use of 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles from this event.

Tiffany A. Traina, MD, discussed the ASCENT Trial examining patients with triple negative breast cancer.

During a Targeted Oncology case-based roundtable event Thomas E. Stinchcombe, MD, discussed the case of a 53-year-old patient with extensive-stage small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Jan A. Burger, MD, PhD, discussed data supporting the use of ibrutinib, acalabrutinib, and zanubrutinib for first-line treatment of chronic lymphocytic leukemia.

During a Targeted Oncology case-based roundtable event, Rana R. McKay, MD, discussed updates to key trials in advanced clear cell renal cell carcinoma.

During a live virtual event, Daneng Li, MD, discussed the case of a 77-year-old woman with stage IV hepatocellular cancer and a Child-Pugh score of A. This is the first of 2 articles from this event.

During a case-based roundtable event, Joshua K. Sabari, MD, discussed the case of a 73-year-old woman with extensive-stage small cell lung cancer.

During a Targeted Oncology live virtual event, Martin F. Dietrich, MD, PhD, discussed data from 3 trials of immunotherapy agents for patients with non–small cell lung cancer with high PD-L1 expression.

During a Targeted Oncology case-based roundtable event, Nelson Jen An Chao, MD, discussed risk management and treatment of patients with steroid-refractory acute graft-versus-host-disease as well as chronic graft-versus-host disease.

During a Targeted Oncology case-based roundtable event, Peter Voorhees, MD, discussed therapy options and transplant eligibility for patients with multiple myeloma.

During a Targeted Oncology case-based event, Chung-Han Lee, MD, PhD, and Bradley A. McGregor, MD, discussed the case of a patient with recurrent metastatic renal cell carcinoma and that of a patient at risk of recurrence following resection.

During a Targeted Oncology case-based roundtable event, John N. Allan, MD, discussed the factors for choosing treatment for chronic lymphocytic leukemia with a Bruton tyrosine kinase inhibitor.

During a Targeted Oncology case-based roundtable event, Antoinette Wozniak, MD, discussed the results of the IMpower 133 and CASPIAN trials of new agents for treating extensive-stage small cell lung cancer.

During a live virtual event, Adam J. Schoenfeld, MD, discussed the updated 3-year results of the CheckMate 9LA trial of nivolumab, ipilimumab, and 2 cycles of chemotherapy for patients with advanced non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Stephen Ansell, MD, PhD, discussed the options for third-line therapy for relapsed/refractory diffuse large B-cell lymphoma.